27258-33-9Relevant articles and documents
MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF
-
Paragraph 0262-0263, (2021/05/21)
Hydantoin based compounds useful as inhibitors of matrix metalloproteinases (MMPs), particularly macrophage elastase (MMP-12) are described. Also described are related compositions and methods of using the compounds to inhibit MMP-12 and treat diseases mediated by MMP-12, such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, nonalcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.
Preparation method of 2-(4-bromo-1-methyl-1H-pyrazol-5-yl)ethanamine
-
Paragraph 0019; 0022; 0023; 0030; 0031, (2017/08/30)
The invention relates to a preparation method of 2-(4-bromo-1-methyl-1H-pyrazol-5-yl)ethanamine. The method comprises the following steps: reacting 1-methylpyrazole used as a raw material to obtain 1-methyl-1H-pyrazole-5-carbaldehyde; adding piperidine and pyridine to obtain a solid 3-(1-methyl-1H-pyrazole-5-yl) acrylic acid; further, adding palladium on carbon into a methanol solution, and introducing hydrogen to obtain 3-(1-methyl-1H-pyrazol-5-yl) propionic acid; furthermore, reacting under roles of bromine and saturated sodium sulphite solution, and performing spinning drying to obtain a solid 3-(4-bromo-1-methyl-1H-pyrazol-5-yl) propionic acid; adding thionyl chloride, tetrahydrofuran, and stronger ammonia water, reacting, dissolving out methyl alcohol, purifying silica gel, eluting ethyl acetate in sequence to obtain 3-(4-bromo-1-methyl-1H-pyrazol-5-yl) propanamide; finally adding NaOH and bromine, and performing ice-bath to obtain 2-(4-bromo-1-methyl-1H-pyrazol-5-yl)ethanamine. The method has the advantages of being clear in steps, little in waste, high in yield, easy to operate and capable of saving raw materials.
Spin transition in the molecular heterospin complex of Cu(hfac)2 with 4,4,5,5-tetramethyl-2-(1-methylpyrazol-5-yl)-4,5-dihydroimidazole-1-oxyl 3-oxide
Fokin,Kostina,Tret'yakov,Romanenko,Bogomyakov,Sagdeev,Ovcharenko
, p. 661 - 671 (2014/01/23)
The synthesis, structure, and magnetic properties of the products of the reaction for Cu(hfac)2 (hfac is hexafluoroacetylacetonate) with spin-labeled nitronyl nitroxides 4,4,5,5-tetramethyl-2-(1-R-1H-pyrazol-5-yl)-3- imidazoline-1-oxyl 3-oxides L5/R (R = Me, Et, Pr, Bu), viz., binuclear complex [Cu(hfac)2L5/Me]2 and chain polymer complexes [Cu(hfac)2L5/R]n, are described. The polymer heterospin chains are built according to head-to-head (R = Me, Et, Pr, Bu) and head-to-tail (R = Pr, Bu) motifs. Compound [Cu(hfac)2L5/Me]2 is characterized by the ability to reveal the reversible effect of thermally induced spin transition at a temperature about 75 K (without hysteresis). In the set of heterospin CuII compounds with spin-labeled pyrazoles, this is the earlier unknown example of a molecular complex exhibiting a similar magnetic anomaly.